Skip to main content
SpringerLink
Log in

Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Inconsistent results regarding the association between statin use and risk of Parkinson’s disease (PD) have been reported. We therefore examined the association between statin use and risk of PD by conducting a detailed meta-analysis of all observational studies published regarding this subject. A literature search in the PubMed database was undertaken through April 2012, looking for observational studies evaluating the association between statin use and risk of PD. Combined relative risk (RR) estimates and 95 % confidence intervals (CIs) were calculated using a random-effects model. Subgroup and sensitivity analyses were also performed. A total of eight (five case–control and three cohort) studies contributed to the analysis. There was heterogeneity and publication bias among the studies. Statin use significantly reduced the risk of PD by 23 % (RR 0.77, 95 % CI 0.64–0.92, p = 0.005). However, long-term statin use did not significantly affect the risk of PD (RR 0.72, 95 % CI 0.45–1.13, p = 0.15). Stratification of studies by age and smoking status significantly affected the final estimate (age-adjusted RR 0.61, 95 % CI 0.42–0.86, p = 0.005; age-not-adjusted RR 0.93, 95 % CI 0.83–1.05, p = 0.23 and smoking-adjusted RR 0.60, 95 % CI 0.42–0.87, p = 0.007; smoking-not-adjusted RR 0.92, 95 % CI 0.82–1.02, p = 0.10). Furthermore, sensitivity analysis confirmed the stability of results. Our meta-analysis supports the hypothesis that statin use reduced the risk of PD. Nevertheless, more randomized clinical trials and observational studies are required to confirm this association with underlying biological mechanisms in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339:1044–1053

    Article  PubMed  CAS  Google Scholar 

  2. Schapira AH (2006) Etiology of Parkinson’s disease. Neurology 66:S10–S23

    Article  PubMed  Google Scholar 

  3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 26:S1–S58

    Article  PubMed  Google Scholar 

  4. Lamb E (2009) Top 200 drugs of 2008. http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed 2 May 2012

  5. Becker C, Meier CR (2009) Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin Drug Saf 8:261–271

    Article  PubMed  CAS  Google Scholar 

  6. Wood WG, Eckert GP, Igbavboa U, Muller WE (2010) Statins and neuroprotection: a prescription to move the field forward. Ann NY Acad Sci 1199:69–76

    Article  PubMed  CAS  Google Scholar 

  7. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA (2011) Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 230:27–34

    Article  PubMed  CAS  Google Scholar 

  8. Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037:1–6

    Article  PubMed  CAS  Google Scholar 

  9. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C (2007) Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord 22:377–381

    Article  PubMed  Google Scholar 

  10. de Lau LM, Stricker BH, Breteler MM (2007) Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 22:1985–1987

    Article  PubMed  Google Scholar 

  11. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20

    Article  PubMed  Google Scholar 

  12. Becker C, Jick SS, Meier CR (2008) Use of statins and the risk of Parkinson’s disease: a retrospective case–control study in the UK. Drug Saf 31:399–407

    Article  PubMed  CAS  Google Scholar 

  13. Samii A, Carleton BC, Etminan M (2008) Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 15:1272–1273

    Article  PubMed  CAS  Google Scholar 

  14. Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2008) Statin use and the risk of Parkinson disease. Neurology 70:1418–1422

    Article  PubMed  CAS  Google Scholar 

  15. Ritz B, Manthripragada AD, Qian L, Schernhammer E, Wermuth L, Olsen J, Friis S (2010) Statin use and Parkinson’s disease in Denmark. Mov Disord 25:1210–1216

    Article  PubMed  Google Scholar 

  16. Gao X, Simon KC, Schwarzschild MA, Ascherio A (2012) Prospective study of statin use and risk of Parkinson disease. Arch Neurol 69:380–384

    Article  PubMed  Google Scholar 

  17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357

    Article  Google Scholar 

  18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622

    Article  PubMed  CAS  Google Scholar 

  19. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22

    Article  Google Scholar 

  20. Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688–1695

    Article  PubMed  Google Scholar 

  21. Ottawa Hospital Research Institute (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 May 2012

  22. Zhang J, Yu KF (1998) What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690–1691

    Article  PubMed  CAS  Google Scholar 

  23. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  PubMed  CAS  Google Scholar 

  24. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  26. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219

    Article  PubMed  Google Scholar 

  27. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012

    Article  PubMed  CAS  Google Scholar 

  28. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol 150:963–976

    Article  PubMed  CAS  Google Scholar 

  29. Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson’s—divergent causes, convergent mechanisms. Science 304:1120–1122

    Article  PubMed  CAS  Google Scholar 

  30. Devaraj S, Chan E, Jialal I (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91:4489–4496

    Article  PubMed  CAS  Google Scholar 

  31. Resch U, Tatzber F, Budinsky A, Sinzinger H (2006) Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61:262–274

    Article  PubMed  CAS  Google Scholar 

  32. Obata T, Yamanaka Y (2000) Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 860:166–169

    Article  PubMed  CAS  Google Scholar 

  33. Murtola TJ, Tammela TL, Mllttlnen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A (2010) Prostate cancer and PSA among statin users in the Finnish Prostate Cancer Screening Trial. Int J Cancer 127:1650–1659

    Article  PubMed  CAS  Google Scholar 

  34. Schachter M (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–125

    Article  Google Scholar 

  35. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11–23

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Dimple Kondal, Senior scientist (Biostatistician), Centre for excellence, Public Health Foundation, India for helping with the data analysis.

Conflicts of interest

No potential conflict of interest relevant to this article was reported. No funding was provided for this analysis.

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar, 160062, Punjab, India

    Krishna Undela, Kapil Gudala, Swathi Malla & Dipika Bansal

Authors
  1. Krishna Undela
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil Gudala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Swathi Malla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dipika Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Krishna Undela.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Undela, K., Gudala, K., Malla, S. et al. Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies. J Neurol 260, 158–165 (2013). https://doi.org/10.1007/s00415-012-6606-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6606-3

Keywords

Search

Navigation